Novel Actions of Metformin to Augment Resistance Training Adaptations in Older Ad

二甲双胍在旧广告中增强抗阻训练适应性的新作用

基本信息

  • 批准号:
    9267120
  • 负责人:
  • 金额:
    $ 55.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-30 至 2019-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The loss of skeletal muscle mass and strength with advancing age reduces quality of life and is a major factor limiting an elderly person's chance of living independently. Progressive resistance exercise training (PRT) is the most effective intervention identified to increase muscular strength and combat muscle atrophy of aging; however, overall the muscle response to PRT is blunted and highly variable in the elderly. Our research team has determined that the abundance of anti-inflammatory, alternatively activated M2 macrophages in muscle predicts response to PRT in the elderly; those with the highest number of M2 macrophages and lowest inflammatory gene expression prior to the start of training gained the most mass. Further, reexamination of muscle biopsies obtained in a study on insulin resistance showed that metformin treatment increased M2 macrophage abundance, and decreased inflammatory cytokine gene expression. These provocative findings have led us to our central hypothesis that adjuvant metformin may improve the responses to PRT in the elderly by altering the muscle tissue inflammatory environment, thereby enhancing mechanisms that drive PRT-induced myofiber hypertrophy. In Aim 1, we will determine if metformin treatment augments skeletal muscle size and strength gains in conjunction with PRT in older, functionally limited adults. Participants will be recruited and randomized to receive either placebo or metformin for 2 weeks followed by a 14 week PRT program with continued drug/placebo treatment. Gains in muscle size and strength will be quantified. In Aim 2, we will identify cellula and molecular responses in muscle to metformin which are associated with improved response to PRT. Muscle macrophages, inflammatory gene expression and anabolic and inflammatory signaling pathways will be examined in muscle biopsies. Finally, mechanisms underlying metformin effects on muscle response to training, using a human muscle cell culture system modeling exercise and the muscle microenvironment, will be explored in Aim 3. Prospective identification of individuals likely to be refractory to routine exercise programs, and determining the effectiveness of metformin in improving muscle growth response to PRT, may contribute to the development of an affordable, personalized approach to maintain or restore skeletal muscle mass and strength, thereby promoting longer healthspan.
描述(由申请人提供):随着年龄的增长,骨骼肌质量和力量的损失降低了生活质量,是限制老年人独立生活的主要因素。渐进式抗阻运动训练(PRT)是最有效的干预措施,以增加肌肉力量和对抗衰老的肌肉萎缩;然而,总体而言,肌肉对PRT的反应是迟钝的,在老年人中变化很大。我们的研究小组已经确定,肌肉中大量的抗炎、替代性激活的M2巨噬细胞预测了老年人对PRT的反应;在训练开始前,M2巨噬细胞数量最多、炎症基因表达最低的人获得了最多的质量。此外,对胰岛素抵抗研究中获得的肌肉活检的重新检查表明,二甲双胍治疗增加了M2巨噬细胞丰度,并降低了炎性细胞因子基因表达。这些激动人心的发现使我们得出了我们的中心假设,即二甲双胍辅助治疗可能通过改变肌肉组织炎症环境来改善老年人对PRT的反应,从而增强驱动PRT诱导的肌纤维肥大的机制。在目标1中,我们将确定二甲双胍治疗是否能增加老年功能受限成人的骨骼肌大小和力量。将招募受试者并随机接受安慰剂或二甲双胍治疗2周,随后进行14周PRT计划,继续药物/安慰剂治疗。肌肉大小和力量的增加将被量化。在目标2中,我们将确定肌肉中对二甲双胍的细胞和分子反应,这些反应与对PRT的反应改善相关。将在肌肉活检中检查肌肉巨噬细胞、炎症基因表达以及合成代谢和炎症信号通路。最后,二甲双胍影响肌肉对训练反应的潜在机制,将在目标3中使用人体肌肉细胞培养系统建模运动和肌肉微环境进行探索。前瞻性地识别可能对常规锻炼计划难治的个体,并确定 二甲双胍在改善对PRT的肌肉生长反应方面的有效性,可能有助于开发一种负担得起的、个性化的方法来维持或恢复骨骼肌质量和强度,从而促进更长的健康寿命。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARCAS M BAMMAN其他文献

MARCAS M BAMMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARCAS M BAMMAN', 18)}}的其他基金

Genetics of Osteoarthritis and Joint Replacement Recovery: Key to Precision Rehabilitation
骨关节炎的遗传学和关节置换恢复:精准康复的关键
  • 批准号:
    9757613
  • 财政年份:
    2018
  • 资助金额:
    $ 55.23万
  • 项目类别:
The Exercise and Physical Activity Collaborative Team (ExPACT): a Proposed MoTrPAC Clinical Center
锻炼和身体活动协作团队 (ExPACT):拟建 MoTrPAC 临床中心
  • 批准号:
    10265096
  • 财政年份:
    2016
  • 资助金额:
    $ 55.23万
  • 项目类别:
The Exercise and Physical Activity Collaborative Team (ExPACT): a Proposed MoTrPAC Clinical Center
锻炼和身体活动协作团队 (ExPACT):拟建 MoTrPAC 临床中心
  • 批准号:
    10391628
  • 财政年份:
    2016
  • 资助金额:
    $ 55.23万
  • 项目类别:
The Exercise and Physical Activity Collaborative Team (ExPACT): a Proposed MoTrPAC Clinical Center
锻炼和身体活动协作团队 (ExPACT):拟建 MoTrPAC 临床中心
  • 批准号:
    9246126
  • 财政年份:
    2016
  • 资助金额:
    $ 55.23万
  • 项目类别:
Novel Actions of Metformin to Augment Resistance Training Adaptations in Older Ad
二甲双胍在旧广告中增强抗阻训练适应性的新作用
  • 批准号:
    8720322
  • 财政年份:
    2014
  • 资助金额:
    $ 55.23万
  • 项目类别:
Novel Actions of Metformin to Augment Resistance Training Adaptations in Older Ad
二甲双胍在旧广告中增强抗阻训练适应性的新作用
  • 批准号:
    8928039
  • 财政年份:
    2014
  • 资助金额:
    $ 55.23万
  • 项目类别:
Interdisciplinary Training in Pathobiology and Rehabilitation Medicine
病理生物学和康复医学跨学科培训
  • 批准号:
    8539828
  • 财政年份:
    2012
  • 资助金额:
    $ 55.23万
  • 项目类别:
Interdisciplinary Training in Pathobiology and Rehabilitation Medicine
病理生物学和康复医学跨学科培训
  • 批准号:
    8268265
  • 财政年份:
    2012
  • 资助金额:
    $ 55.23万
  • 项目类别:
Interdisciplinary Training in Pathobiology and Rehabilitation Medicine
病理生物学和康复医学跨学科培训
  • 批准号:
    8843497
  • 财政年份:
    2012
  • 资助金额:
    $ 55.23万
  • 项目类别:
Interdisciplinary Training in Pathobiology and Rehabilitation Medicine
病理生物学和康复医学跨学科培训
  • 批准号:
    9144915
  • 财政年份:
    2012
  • 资助金额:
    $ 55.23万
  • 项目类别:

相似海外基金

Investigating HDAC3 phosphorylation as an epigenetic regulator of memory formation in the adult and aging brain
研究 HDAC3 磷酸化作为成人和衰老大脑记忆形成的表观遗传调节剂
  • 批准号:
    10752404
  • 财政年份:
    2023
  • 资助金额:
    $ 55.23万
  • 项目类别:
The Health of Aging Parents of Adult Children with Serious Conditions
患有严重疾病的成年子女的年迈父母的健康
  • 批准号:
    10660046
  • 财政年份:
    2023
  • 资助金额:
    $ 55.23万
  • 项目类别:
Understanding Longer-Living Older Adult Research: The Summer Program on Aging
了解长寿老年人研究:老龄化夏季项目
  • 批准号:
    476343
  • 财政年份:
    2022
  • 资助金额:
    $ 55.23万
  • 项目类别:
Role of sensory experience in the regulation of plasticity in the developing, adult and aging brain
感官体验在发育、成人和衰老大脑可塑性调节中的作用
  • 批准号:
    RGPIN-2019-04761
  • 财政年份:
    2022
  • 资助金额:
    $ 55.23万
  • 项目类别:
    Discovery Grants Program - Individual
Adult Cognitive and Neurobiological Indicators of Aging: Impact of Adversity and Social Support
成人衰老的认知和神经生物学指标:逆境和社会支持的影响
  • 批准号:
    10365348
  • 财政年份:
    2022
  • 资助金额:
    $ 55.23万
  • 项目类别:
Adult Cognitive and Neurobiological Indicators of Aging: Impact of Adversity and Social Support
成人衰老的认知和神经生物学指标:逆境和社会支持的影响
  • 批准号:
    10700796
  • 财政年份:
    2022
  • 资助金额:
    $ 55.23万
  • 项目类别:
Endogenous barcoding to determine complex dynamics of adult neurogenesis in aging and Alzheimer's disease
内源条形码确定衰老和阿尔茨海默病中成人神经发生的复杂动态
  • 批准号:
    10651861
  • 财政年份:
    2022
  • 资助金额:
    $ 55.23万
  • 项目类别:
Investigating the interface of epigenetics and metabolism underlying memory formation in the adult, aging, and AD brain
研究成人、衰老和 AD 大脑中记忆形成的表观遗传学和代谢界面
  • 批准号:
    10420533
  • 财政年份:
    2022
  • 资助金额:
    $ 55.23万
  • 项目类别:
Endogenous barcoding to determine complex dynamics of adult neurogenesis in aging and Alzheimer's disease
内源条形码确定衰老和阿尔茨海默病中成人神经发生的复杂动态
  • 批准号:
    10846200
  • 财政年份:
    2022
  • 资助金额:
    $ 55.23万
  • 项目类别:
THE DEVELOPMENT OF MECHANISM-BASED ADULT STEM CELL TREATMENTS TO COMBAT AGING PATHOLOGIES
开发基于机制的成人干细胞疗法来对抗衰老病理学
  • 批准号:
    10721544
  • 财政年份:
    2022
  • 资助金额:
    $ 55.23万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了